Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Reilly

Showing results (571-580 of 605) with videos related to

Pageof 61
Sort By:
Leukemia|January 26, 2007
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupG Barosi, C Besses, G Birgegard, et al.
PLOS Mental Health|February 9, 2026
Realist assessment of fidelity during the implementation of the PARTNERS collaborative care intervention for people with diagnoses of severe mental illness within a cluster randomised controlled trialCharley Hobson-Merrett, Julia Frost, Ruth Gwernan-Jones, et al.
British Journal of Haematology|June 5, 2003
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemiasRory S Care, Peter J M Valk, Anne C Goodeve, et al.
Haematologica|September 26, 2008
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disordersNasios Fourouclas, Juan Li, Daniel C Gilby, et al.
British Journal of Haematology|November 26, 2009
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus processGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Medical Care|February 19, 1999
Monitoring the health status and impact of treatment on Americans: the Medicare Beneficiary Health Status RegistryA M McBean, C F Turner, L K Fitterman, et al.
Blood|July 5, 2005
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)Giovanni Barosi, Dominique Bordessoule, Jean Briere, et al.
British Journal of Haematology|February 13, 2001
Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemiaD Rowe, S J Cotterill, F M Ross, et al.
Journal of Clinical Pathology|January 30, 2015
Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service modelC Dalley, H Basarir, J G Wright, et al.
British Journal of Haematology|June 26, 2014
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012John T Reilly, Mary Frances McMullin, Philip A Beer, et al.
Pageof 61

Showing results (571-580 of 605) with videos related to

Sort By:
Pageof 61
Leukemia|January 26, 2007
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupG Barosi, C Besses, G Birgegard, et al.
PLOS Mental Health|February 9, 2026
Realist assessment of fidelity during the implementation of the PARTNERS collaborative care intervention for people with diagnoses of severe mental illness within a cluster randomised controlled trialCharley Hobson-Merrett, Julia Frost, Ruth Gwernan-Jones, et al.
British Journal of Haematology|June 5, 2003
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemiasRory S Care, Peter J M Valk, Anne C Goodeve, et al.
Haematologica|September 26, 2008
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disordersNasios Fourouclas, Juan Li, Daniel C Gilby, et al.
British Journal of Haematology|November 26, 2009
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus processGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Medical Care|February 19, 1999
Monitoring the health status and impact of treatment on Americans: the Medicare Beneficiary Health Status RegistryA M McBean, C F Turner, L K Fitterman, et al.
Blood|July 5, 2005
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)Giovanni Barosi, Dominique Bordessoule, Jean Briere, et al.
British Journal of Haematology|February 13, 2001
Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemiaD Rowe, S J Cotterill, F M Ross, et al.
Journal of Clinical Pathology|January 30, 2015
Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service modelC Dalley, H Basarir, J G Wright, et al.
British Journal of Haematology|June 26, 2014
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012John T Reilly, Mary Frances McMullin, Philip A Beer, et al.
Pageof 61